Loading news...
Shares of Gamehost Inc. (TSE: GH - Get Free Report) crossed below its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of C$11.76 and traded as low as C$11.70. Gamehost shares last traded at C$11.76, with a volume of 5,300 shares trading hands. Gamehost Stock Performance The stock has
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present 28 abstracts, including 3 oral sessions, showcasing advances in methylation-based tumor classification and liquid biopsy technology at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, California taking place April 17 - 22, 2026. Key data that will be presented include: An oral present.
Algert Global LLC raised its holdings in Guardant Health, Inc. (NASDAQ: GH) by 169.1% during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 120,114 shares of the company's stock after purchasing an additional 75,474 shares during the period.
PALO ALTO, Calif. & HONG KONG--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the launch of the Shield™ multi-cancer detection (MCD) laboratory developed test (LDT) in multiple markets in Asia. The Shield MCD test is a methylation-based blood test for the detection of multiple cancer types including bladder, colorectal, breast, prostate, esophageal, gastric, liver, lung, ovarian and pancreas cancer in individuals aged 45 or older who a.
Aquatic Capital Management LLC increased its position in Guardant Health, Inc. (NASDAQ: GH) by 17.7% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 183,576 shares of the company's stock after acquiring an additional 27,612 shares during the period.
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the results of a new national survey conducted on its behalf by The Harris Poll with findings demonstrating that more than 9 out of 10 Americans ages 45 and over believe in ensuring broader coverage for blood-based colorectal cancer (CRC) screening, including new innovations like Shield™ by Guardant, a methylation partitioning cell-free DNA (mp-cfDNA) test and the first.
We maintain our valuation discipline and our focus on companies with competitive advantages and skilled management teams that we believe are executing better than their peers. We initiated a position in Tractor Supply after recent share weakness created a compelling entry point, in our view. Tyler Technologies was sold because the software provider's revenue growth has decelerated, which reduced our conviction in its upside potential.
Guardant Health, Inc. (GH) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Shares of Guardant Health, Inc. (NASDAQ: GH - Get Free Report) have received an average rating of "Moderate Buy" from the twenty-three brokerages that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, one has given a hold rating and twenty-one have issued a buy rating on the
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the Shield™ by Guardant blood-based screening test is now widely accessible for physician order through the nationwide connectivity of Quest Diagnostics, equipping clinicians with access to blood-based screening innovation for colorectal cancer (CRC) through one of the largest diagnostic ecosystems in the United States. Shield is the first and only blood test to rec.
bioAffinity leans on its CyPath Lung sputum test for early lung cancer detection, while Guardant Health expands liquid biopsy and screening. Which strategy is ahead?
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the launch of Shield Across America, a historic coast-to-coast mobile screening tour bringing Shield, the first and only FDA-approved blood test as a primary colorectal cancer (CRC) screening option and recommended in national guidelines, directly to over 100 communities across the country from Las Vegas to Hartford, Atlanta and more. From national sporting events to rur.
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its partnership with actor and cancer advocate Patrick Dempsey to increase awareness about colorectal cancer (CRC) screening and the Shield® blood test. Approved by the U.S. Food and Drug Administration (FDA) in 2024 and recommended in national guidelines, Shield offers an easier way to screen for colorectal cancer (CRC) with just a blood draw for eligible individuals 45.
Coherent is expected to continue to benefit from a transition to products that enable faster throughput speeds, while prior constraints on manufacturing capacity appear to be alleviating. BrightSpring Health Services reported another strong quarter with both revenues and EBITDA up significantly, far outpacing its historical growth rate prior to going public in 2024. Varonis Systems, which provides data protection security software, delivered disappointing earnings results and an outlook below expectations.
PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on February 23, 2026, the Compensation Committee of Guardant's Board of Directors approved the granting of restricted stock units (“RSUs”) representing 41,852 shares of its common stock to 88 new non-executive employees and one non-qualified stock option award to purchase 4,965 shares of its common stock to one new non-executive employee with a grant date of Februar.
Investor attention turned more intensely to the scale, timing, and funding of AI-related capital commitments, prompting renewed debate about whether expectations were running ahead of eventual monetization. The Russell 1000 Value Index returned 3.81% during the quarter, outperforming the Russell 1000 Growth Index's return of 1.12% by nearly 270 basis points. Under its 'pivot to growth' strategy, Teva has expanded its biosimilars portfolio and strengthened its generics business, returning that segment to positive growth.
Granite Investment Partners LLC lessened its stake in Guardant Health, Inc. (NASDAQ: GH) by 52.1% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 185,301 shares of the company's stock after selling 201,565 shares during the period. Granite Investment Partners LLC owned
Assetmark Inc. increased its holdings in shares of Guardant Health, Inc. (NASDAQ: GH) by 18,838.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 13,257 shares of the company's stock after acquiring an additional 13,187 shares during the period. Assetmark Inc.'s holdings in
Guardant Health, Inc. (GH) Q4 2025 Earnings Call Transcript
Although the revenue and EPS for Guardant Health (GH) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.